美国医疗保险公司 (CMS) 地向受益者提供未经批准的大麻衍生类大麻素. CMS quietly offers unapproved hemp-derived cannabinoids to Medicare beneficiaries.

CMS正在地通过试点项目向医疗保险受益者提供未经验证的麻衍生大麻类产品, 包括那些含有delta-9 THC的药物. 没有FDA批准或医生的处方. CMS is quietly offering unvalidated hemp-derived cannabinoid products, including those with delta-9 THC, to Medicare beneficiaries through pilot programs without FDA approval or physician prescriptions. 批评者警告说,这使老年患者面临无法控制的风险, 而政府则认为法定豁免可以防止司法审查, 国会监督是适当的检查. Critics warn this exposes elderly patients to uncontrolled risks, while the government argues statutory exemptions prevent judicial review and that congressional oversight is the proper check.